research Successful Treatment of Severe Atopic Dermatitis and Alopecia Universalis With Upadacitinib in a 29-Year-Old Male Patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
Search
forLearn
0 / 0 results — no results
Research
5 / 10 results
research Update: Baricitinib for Alopecia Areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Drug Interactions Between Common Dermatological Medications and the Oral Anti-Covid-19 Agents Nirmatrelvir-Ritonavir and Molnupiravir
Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
Community Join
0 / 0 results — no results